MCID: NRC002
MIFTS: 62

Narcolepsy malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Narcolepsy

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 23Genetics Home Reference, 46NINDS, 47Novoseek, 12DISEASES, 36MeSH, 65UMLS, 51Orphanet, 24GTR, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Narcolepsy:

Name: Narcolepsy 10 45 23 46 47 12 36 65
Narcolepsy-Cataplexy Syndrome 45 65
Narcoleptic Syndrome 45 23
Narcolepsy-Cataplexy 51 24
Gelineau Syndrome 45 23
 
Paroxysmal Sleep 10 45
Narcolepsy, Without Cataplexy 10
Narcolepsy Without Cataplexy 51
Gelineau's Syndrome 45
Gélineau Disease 51

Characteristics:

Orphanet epidemiological data:

51
narcolepsy-cataplexy:
Prevalence: 1-5/10000 (Europe); Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy
narcolepsy without cataplexy:
Age of onset: Adolescent,Adult,Childhood; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology10 DOID:8986
ICD9CM29 347.0
MeSH36 D009290
NCIt42 C84489
Orphanet51 2073, 83465
ICD10 via Orphanet28 G47.4
MESH via Orphanet37 D009290
UMLS via Orphanet66 C0027404, C0751362
UMLS65 C0027404, C0751362

Summaries for Narcolepsy

About this section
NIH Rare Diseases:45 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. people with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). the disorder is usually sporadic but some cases are familial. there is no cure, but some symptoms can be managed with medicines and lifestyle changes. last updated: 4/27/2015

MalaCards based summary: Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to atopic dermatitis and systemic lupus erythematosus, and has symptoms including hallucinations, muscle weakness and memory impairment. An important gene associated with Narcolepsy is HCRT (Hypocretin (Orexin) Neuropeptide Precursor), and among its related pathways are CTLA4 Signaling and Staphylococcus aureus infection. The drugs amphetamine and dextroamphetamine sulfate have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and prostate, and related mouse phenotypes are nervous system and behavior/neurological.

Disease Ontology:10 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

Genetics Home Reference:23 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence.

NINDS:46 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles normally. At various times throughout the day, people with narcolepsy experience irresistable bouts of

Wikipedia:68 Narcolepsy is a chronic neurological disorder involving the loss of the brain\'s ability to regulate... more...

Related Diseases for Narcolepsy

About this section

Diseases in the Narcolepsy family:

Narcolepsy 2 Narcolepsy 7
Narcolepsy 5 Narcolepsy 1
Narcolepsy 6 Narcolepsy 3
Narcolepsy 4 Narcolepsy Risk Factor

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 514)
idRelated DiseaseScoreTop Affiliating Genes
1atopic dermatitis30.8ATXN3, HCRT, HTR2A, MOG
2systemic lupus erythematosus30.7DNMT1, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFSF4
3obstructive sleep apnea30.6HCRT, HTR2A, TNF
4psoriasis30.6HLA-DQB1, HLA-DRB1
5cerebellar ataxia, deafness, and narcolepsy, autosomal dominant12.6
6narcolepsy 112.6
7narcolepsy 712.5
8narcolepsy 312.4
9narcolepsy 212.3
10narcolepsy 512.3
11narcolepsy 612.3
12narcolepsy 412.3
13narcolepsy risk factor12.2
14idiopathic inflammatory myopathy10.7HCRT, HLA-DQB1
15lichen planus pemphigoides10.7HLA-DQB1, HLA-DRB1
16congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome10.7HLA-DRB1, TNF
17tucker syndrome10.7HLA-DQA1, HLA-DQB1, HLA-DRB1
18heavy chain deposition disease10.7HLA-DQB1, HLA-DRB1
19autoimmune polyglandular syndrome type 210.7HLA-DQB1, HLA-DRB1, TNF
20pulmonary coin lesion10.7HLA-DQA1, HLA-DQB1, HLA-DRB1
21best1 retinopathy10.7HLA-DQB1, HLA-DRB1, TNF
22non-distal monosomy 10q10.7HLA-DQB1, HLA-DRB1, TNF
23lymphocytic choriomeningitis10.7HLA-DQB1, HLA-DRB1, TNF
24moderately severe hemophilia a10.7HLA-DQB1, HLA-DRB1, TNF
25pediatric t-cell leukemia10.7HLA-DRB1, MOG
26cytoplasmic body myopathy10.7HLA-DQB1, HLA-DRB1, TNF
27pulmonary nodular lymphoid hyperplasia10.7HLA-DQA1, HLA-DQB1, HLA-DRB1
28microsomia hemifacial radial defects10.7HLA-DRB1, TNF
29duodenum cancer10.7HLA-DQA1, HLA-DQB1, TNF
30neutropenia10.7HCRT, HLA-DRB1, MOG
31drug-induced mental disorder10.7HLA-DQA1, HLA-DRB1, TNF
32hepatoid adenocarcinoma10.7HLA-DQB1, HLA-DRB1, TNF
33idiopathic juxtafoveal retinal telangiectasia10.7HLA-DQB1, HLA-DRB1
34kernicterus due to isoimmunization10.7HLA-DQB1, HLA-DRB1, TNF
35byssinosis10.7HLA-DQB1, HLA-DRB1, TNF
36cryptosporidiosis10.7HLA-DQA1, HLA-DRB1, TNF
37lichtenstein syndrome10.6HLA-DQB1, HLA-DRB1
38acute female pelvic peritonitis10.6HCRTR1, HCRTR2
39inflammatory spondylopathy10.6HCRT, HLA-DRB1, MOG, TNF
40progressive relapsing multiple sclerosis10.6HLA-DRB1, MOG, TNF
41red cell phospholipid defect with hemolysis10.6HLA-DQB1, HLA-DRB1
42hypertonia10.6CPT1B, HCRT, HLA-DQB1, HLA-DRB1
43artery disease10.6HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
44diplegia of upper limb10.6COMT, HCRT, HTR2A
45periampullary adenoma10.6HCRT, HTR2A, TNF
46pupil disease10.6HLA-DRB1, MOG, TNF
47lung lymphoma10.6HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
48zebra body myopathy10.6COMT, HTR2A, TNF
49liver fibroma10.6HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
50ring chromosome 14 syndrome10.6COMT, HTR2A

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to narcolepsy

Symptoms for Narcolepsy

About this section

Symptoms:

 51 (show all 11)
  • sleep and vigilance disorders
  • somnolence/hypersomnia/parasomnia
  • troubles of memory/amnesia/hypermnesia
  • delirium/hallucination
  • muscle weakness/flaccidity
  • anomalies of eyes and vision
  • abnormal eye movements/oculomotor disorder
  • collapse/sudden death/cardiac arrest/cardiorespiratory arrest
  • speech troubles/aphasia/dysphasia/echolalia/mutism/logorrhea/dysprosodia
  • generalized obesity
  • psychic/behavioural troubles

HPO human phenotypes related to Narcolepsy:

(show all 9)
id Description Frequency HPO Source Accession
1 hallucinations hallmark (90%) HP:0000738
2 muscle weakness hallmark (90%) HP:0001324
3 memory impairment hallmark (90%) HP:0002354
4 sleep disturbance hallmark (90%) HP:0002360
5 reduced consciousness/confusion hallmark (90%) HP:0004372
6 abnormality of eye movement typical (50%) HP:0000496
7 obesity occasional (7.5%) HP:0001513
8 sudden cardiac death occasional (7.5%) HP:0001645
9 neurological speech impairment occasional (7.5%) HP:0002167

Drugs & Therapeutics for Narcolepsy

About this section

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 86)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 2, Phase 3, Phase 1308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Modafinilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 019268693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
3
Gabapentinapproved, investigationalPhase 426960142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Kit
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
Gralise
Gralise Starter Pack
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
4
RasagilineapprovedPhase 453136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
5
Pramipexoleapproved, investigationalPhase 4137104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
KBio2_007476
 
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole Dihydrochloride Extended-Release
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
6
RibavirinapprovedPhase 494836791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
Ibavyr
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
Moderiba
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
 
NSC 163039
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribasphere Ribapak
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
7Dopamine AgentsPhase 4, Phase 2, Phase 3, Phase 13084
8Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 114795
9AnestheticsPhase 4, Phase 3, Phase 2, Phase 17385
10Protective AgentsPhase 4, Phase 1, Phase 25651
11Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 218510
12Contraceptives, OralPhase 4, Phase 2, Phase 3, Phase 03734
13Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 110016
14Anesthetics, IntravenousPhase 4, Phase 3, Phase 2, Phase 11943
15Anesthetics, GeneralPhase 4, Phase 3, Phase 2, Phase 12274
16Pharmaceutical SolutionsPhase 4, Phase 37004
17
R4733Phase 4, Phase 3, Phase 2, Phase 138502-85-25360545
Synonyms:
4-Hydroxybuttersaeure natriumsalz
4-Hydroxybutyrate sodium
4-Hydroxybutyric acid monosodium salt
4-Hydroxybutyric acid sodium salt
502-85-2
ARONIS24196
Anetamin
BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT
Butanoic acid, 4-hydroxy-, monosodium salt
Butanoic acid, 4-hydroxy-, sodium salt
Butanoic acid, 4-hydroxy-, sodium salt (1:1)
Butyric acid, 4-hydroxy-, monosodium salt
Butyric acid, 4-hydroxy-, monosodium salt (8CI)
C4H7O3.Na
CHEMBL1200682
CID10412
D05866
EB 27
EINECS 207-953-3
GHB
Gamma OH
H-4040
H3635_SIGMA
HMS2091E15
Hydroxybutyric acid monosodium salt
 
LS-48077
MolPort-001-766-711
MolPort-006-717-541
NSC 84223
Natrium 4-hydroxybutyrat
OR28769
Oxybate sodium
Sodium 4-hydroxybutyrate
Sodium Oxybate [USAN]
Sodium Oxybutyrate
Sodium gamma-hydroxybutyrate
Sodium gammahydroxybutyrate
Sodium oxybate
Sodium oxybate (USAN)
Sodium-4-hydroxybutyrate
Somsanit
UNII-7G33012534
WY 3478
WY-3478
Xyrem
Xyrem (TN)
gamma-Hydroxy sodium butyrate
gamma-Hydroxybutyrate sodium
gamma-Hydroxybutyrate sodium salt
gamma-Hydroxybutyric acid sodium salt
gamma-Hydroxybutyric acid, sodium salt
18Wakefulness-Promoting AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 0179
19ArmodafinilPhase 4, Phase 3, Phase 2, Phase 1, Phase 0192
20Central Nervous System StimulantsPhase 4, Phase 3, Phase 2, Phase 1, Phase 01721
21VaccinesPhase 46085
22Psychotropic DrugsPhase 45501
23Tranquilizing AgentsPhase 43597
24Excitatory Amino AcidsPhase 41109
25Calcium, DietaryPhase 44678
26Excitatory Amino Acid AntagonistsPhase 41095
27Anti-Anxiety AgentsPhase 41529
28AnalgesicsPhase 4, Phase 39358
29Antimanic AgentsPhase 4663
30AnticonvulsantsPhase 42249
31Antiparkinson AgentsPhase 41312
32calcium channel blockersPhase 41743
33Neuroprotective AgentsPhase 41376
34Dopamine AgonistsPhase 4544
35Interferon-alphaPhase 41028
36AntioxidantsPhase 42442
37interferonsPhase 41930
38
Histamine PhosphateapprovedPhase 3, Phase 290651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
39
Methylphenidateapproved, investigationalPhase 2, Phase 3364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
40
Morphineapproved, investigationalPhase 385557-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
Infumorph
 
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morphine
nchembio.317-comp1
nchembio.64-comp1
41
Pyridoxalapproved, nutraceuticalPhase 316365-22-5, 66-72-81050
Synonyms:
3-HYDROXY-5-(hydroxymethyl)-2-methylisonicotinaldehyde
 
3-Hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde
Pyridoxal
Pyridoxaldehyde
42
Folic Acidapproved, nutraceuticalPhase 3292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
43
Pyridoxineapproved, nutraceuticalPhase 316565-23-61054
Synonyms:
(5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate
12001-78-4
2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin
2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]
2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine
2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine
2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine
2-methyl-4,5-dimethylol-pyridin-3-ol
2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0
3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-, hydrochloride
3-Hydroxy-2-Picoline-4,5-dimethanol
3-Hydroxy-4,5-dihydroxymethyl-2-methylpyridine hydrochloride
3-Hydroxy-4,5-dimethylol-.alpha.-picoline hydrochloride
3-Hydroxy-4,5-dimethylol-alpha-picoline
3-Hydroxy-4,5-dimethylol-alpha-picoline hydrochloride
3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine
4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol
4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol hydrochloride
4,5-bis(hydroxymethyl)-2-methyl-3-pyridinol hydrochloride
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol
4-Deoxypyridoxine 5'-phosphate
47862_SUPELCO
5-Hydroxy-6-methyl-3,4-pyridinedicarbinol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol
5-Hydroxy-6-methyl-3,4-pyridinedimethanol hydrochloride
5-Hydroxy-6-methyl-3,4-pyridinedimethanol, hydrochloride
58-56-0
58-56-0 (HCL)
58-56-0 (hydrochloride)
65-23-6
65-23-6 (Parent)
8059-24-3
85078-23-5
AC-12024
AC-14512
AC-907/25014218
AC1L1AMH
AC1L1LMI
AC1L2XK2
AC1Q22HP
AC1Q2G66
AC1Q3F63
AI3-19016
AIDS-006784
AIDS006784
AR-1A6363
AR-1J1632
Adermin hydrochloride
Adermine
Adermine hydrochloride
Aderomine hydrochloride
Aderoxin
Aderoxine
Alestrol
BB_NC-0050
BIDD:PXR0180
BPBio1_000646
BSPBio_000586
Becilan
Beesix
Benadon
Bonasanit
C00314
C8H11NO3
CAS-58-56-0
CBDivE_015627
CCRIS 1903
CHEBI:16709
CHEBI:30961
CHEMBL1200756
CHEMBL1364
CID104817
CID1054
CID6019
CPD0-1221
Campoviton 6
Cernevit-12
D02179
D025101
D08454
DB00165
EINECS 200-386-2
EINECS 200-603-0
EINECS 232-503-8
Godabion
Gravidox
HMS1569N08
HMS2093L07
HSDB 1212
Hexa-Betalin
Hexa-Betalin (R)
Hexa-betalin (TN)
Hexabetalin
Hexabione hydrochloride
Hexavibex
 
Hexermin
Hexermine
Hexobion
Hydoxin
I02-1897
I02-2297
KST-1A8556
LS-134393
LS-187072
LS-2332
MLS001074329
MLS002153915
MolPort-002-137-856
MolPort-002-319-991
MolPort-005-933-330
NCGC00016261-01
NCGC00164317-01
NCGC00180946-01
NSC 36225
NSC36225
NSC36225 (HCL)
Nestrex
Oprea1_061614
P0561
P4722_SIAL
P5669_SIGMA
P6280_SIGMA
P8666_SIGMA
P9755_SIAL
PN
PN HCl
PYRIDOXINE HYDROCHLORIDE
PYRIDOXINE HYDROCHLORIDE, U.S.P.
Paxadon
Piridossina
Piridossina [DCIT]
Piridoxina
Piridoxina [INN-Spanish]
Prestwick0_000623
Prestwick1_000623
Prestwick2_000623
Prestwick3_000623
Prestwick_925
Pydox
Pyridipca
Pyridox
Pyridoxin
Pyridoxin hydrochloride
Pyridoxine
Pyridoxine (INN)
Pyridoxine HCl
Pyridoxine Hydrochloride
Pyridoxine Hydrochloride (B6)
Pyridoxine [INN:BAN]
Pyridoxine chloride
Pyridoxine hydrochloride
Pyridoxine hydrochloride (JP15/USP)
Pyridoxine hydrochloride [USAN:JAN]
Pyridoxine hydrogen chloride
Pyridoxine monohydrochloride
Pyridoxine, hydrochloride
Pyridoxine-HCl Microencapsulated
Pyridoxinium chloride
Pyridoxinum
Pyridoxinum [INN-Latin]
Pyridoxinum hydrochloricum
Pyridoxinum hydrochloricum (Hungarian)
Pyridoxol
Pyridoxol hydrochloride
Pyridoxol, hydrochloride
Pyridoxolum
Rodex
Rodex (R)
Rodex TD
SMP2_000230
SMR000674613
SPBio_002805
STK177324
STOCK1N-08684
Spondylonal
Tex Six T.R.
TimTec1_000657
UNII-68Y4CF58BV
UNII-KV2JZ1BI6Z
Vitamin B 6
Vitamin B6
Vitamin B6-hydrochloride
Vitamin V6
Vitamin V6 (TN)
Vitamin-?B6
Vitamin-?B6 hydrochloride
Vitaped
WLN: T6NJ B1 CQ D1Q E1Q &GH
ZINC00049154
ZINC21983293
bmse000288
c1302
component of Alestrol
nchembio.93-comp1
pyridoxine
vitamin B6
44VitaminsPhase 33857
45Vitamin B ComplexPhase 32847
46Dopamine Uptake InhibitorsPhase 2, Phase 3, Phase 1925
47Neurotransmitter Uptake InhibitorsPhase 2, Phase 3, Phase 12857
48MicronutrientsPhase 33901
49Histamine H3 AntagonistsPhase 3, Phase 210
50Trace ElementsPhase 33900

Interventional clinical trials:

(show top 50)    (show all 83)
idNameStatusNCT IDPhase
1Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine ChangesCompletedNCT00345800Phase 4
2Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997Phase 4
3An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia FatigueCompletedNCT00678691Phase 4
4Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDSCompletedNCT00118378Phase 4
5"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"CompletedNCT01023672Phase 4
6SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)CompletedNCT02055898Phase 4
7Xyrem and Brain Dopamine in NarcolepsyRecruitingNCT02637076Phase 4
8Pain Expectations in Subjects With OsteoarthritisRecruitingNCT02155257Phase 4
9Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on PrescriptionActive, not recruitingNCT00244465Phase 4
10Effect of Armodafinil on Simulated DrivingNot yet recruitingNCT02468856Phase 4
11Modafinil Treatment for Sleep/Wake Disturbances in Older AdultsTerminatedNCT00626210Phase 4
12Armodafinil for Patients Starting Hepatitis C Virus TreatmentTerminatedNCT01470651Phase 4
13Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseTerminatedNCT01048229Phase 4
14PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107848Phase 3
15Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.CompletedNCT01638403Phase 3
16Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With NarcolepsyCompletedNCT00107796Phase 3
17Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in NarcolepsyCompletedNCT00066170Phase 3
18Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With NarcolepsyCompletedNCT00078377Phase 3
19Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep DisorderCompletedNCT00078312Phase 3
20Trial of Xyrem® (Sodium Oxybate) for the Treatment of NarcolepsyCompletedNCT00132873Phase 3
21Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in NarcolepsyCompletedNCT01067222Phase 3
22Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive SleepinessCompletedNCT00228553Phase 3
23Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic PatientsCompletedNCT00049803Phase 3
24Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00228566Phase 3
25Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With NarcolespyCompletedNCT01067235Phase 3
26Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive SleepinessCompletedNCT00214968Phase 3
27Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)CompletedNCT01800045Phase 3
28Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)CompletedNCT01789398Phase 3
29Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese PatientsCompletedNCT02478580Phase 3
30Modafinil in Cancer Related FatigueCompletedNCT01440621Phase 3
31"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"RecruitingNCT02348593Phase 3
32A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With CataplexyRecruitingNCT02221869Phase 3
33Palliative Morphine With or Without Concurrent ModafinilRecruitingNCT01766323Phase 3
34"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"RecruitingNCT02348606Phase 3
35Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)Active, not recruitingNCT01399606Phase 3
36Methylphenidate to Improve Balance and Walking in MSActive, not recruitingNCT01896700Phase 2, Phase 3
37"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"Enrolling by invitationNCT02348632Phase 3
38Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in NarcolepsyNot yet recruitingNCT02720744Phase 3
39Modafinil to Treat Fatigue in Post-Polio SyndromeTerminatedNCT00067496Phase 3
40A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With NarcolepsyCompletedNCT00424931Phase 2
41A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With NarcolepsyCompletedNCT01006122Phase 2
42A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With NarcolepsyCompletedNCT01681121Phase 2
43A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime SleepinessCompletedNCT01485770Phase 2
44Clarithromycin for the Treatment of HypersomniaCompletedNCT01146600Phase 2
45Flumazenil for the Treatment of Primary HypersomniaCompletedNCT01183312Phase 1, Phase 2
46Methylphenidate and Parkinson's DiseaseCompletedNCT00359723Phase 2
47Sodium Oxybate in Schizophrenia With InsomniaCompletedNCT00594256Phase 2
48Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse HistoriesCompletedNCT00247572Phase 2
49Modafinil vs Placebo for the Treatment of Methamphetamine DependenceCompletedNCT00469508Phase 2
50Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant AbuseCompletedNCT00248092Phase 1, Phase 2

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

About this section

Anatomical Context for Narcolepsy

About this section

MalaCards organs/tissues related to Narcolepsy:

33
Brain, Eye, Prostate, Breast, T cells, Lung, Endothelial

Animal Models for Narcolepsy or affiliated genes

About this section

MGI Mouse Phenotypes related to Narcolepsy:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036319.7ATXN3, COMT, DNMT1, HCRT, HCRTR1, HCRTR2
2MP:00053869.4ATXN3, COMT, DNMT1, HCRT, HCRTR1, HCRTR2

Publications for Narcolepsy

About this section

Articles related to Narcolepsy:

(show top 50)    (show all 732)
idTitleAuthorsYear
1
Biflavone Ginkgetin, a Novel Wnt Inhibitor, Suppresses the Growth of Medulloblastoma. (25821199)
2015
2
Neurocognitive Development and Predictors of L1 and L2 Literacy Skills in Dyslexia: A Longitudinal Study of Children 5-11a88Years Old. (26511662)
2015
3
Spongiotic dermatitis with Langerhans cell microvesicles. (26469341)
2015
4
Usefulness of exercise test in the diagnosis of short QT syndrome. (25833882)
2015
5
Structural neuroimaging in patients with panic disorder: findings and limitations of recent studies. (23793273)
2013
6
The adhesion-GPCR BAI1 regulates synaptogenesis by controlling the recruitment of the Par3/Tiam1 polarity complex to synaptic sites. (23595754)
2013
7
Bioinformatics for microbial genotyping of equine encephalitis viruses, orthopoxviruses, and hantaviruses. (23714768)
2013
8
Articular synovial chondromatosis of the finger. (23596991)
2013
9
Progressive multifocal leukoencephalopathy: clinical and molecular aspects. (21936015)
2012
10
Case report: Evidence of rise in rabies cases in southern Malawi--better preventative measures are urgently required. (23638276)
2012
11
Erythema ab igne as a differential diagnosis of chronic graft versus host disease (GVHD). (22834457)
2012
12
Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis. (22721424)
2012
13
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. (22457212)
2012
14
Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma. (23157525)
2012
15
DP97, a DEAD box DNA/RNA helicase, is a target gene-selective co-regulator of the constitutive androstane receptor. (22910411)
2012
16
Cardiogenic shock in an elderly man caused by left main coronary artery occlusion with spontaneous dissection of right coronary artery. (21152670)
2011
17
The interferon stimulated gene 54 promotes apoptosis. (21190939)
2011
18
Blockade of neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does not predispose to airway bacterial outgrowth. (19751843)
2010
19
The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. (19619936)
2010
20
Characterization of new PPARgamma agonists: analysis of telmisartan's structural components. (19197922)
2009
21
Effects of a diagnosis or family history of alcoholism on the taste intensity and hedonic value of sucrose. (19874171)
2009
22
Phalloplasty and urethroplasty in children with penile agenesis: preliminary report. (17296424)
2007
23
Control of human mesothelin-expressing tumors by DNA vaccines. (17581599)
2007
24
A new generation of metal string complexes: structure, magnetism, spectroscopy, theoretical analysis, and single molecular conductance of an unusual mixed-valence linear [Ni5]8+ complex. (17847146)
2007
25
Confirmation of region-specific patterns of gene expression in the human brain. (17375343)
2007
26
Biochemical characterization of 1-Cys peroxiredoxin from Antrodia camphorata. (17103164)
2007
27
Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. (16443681)
2006
28
The novel centrosomal associated protein CEP55 is present in the spindle midzone and the midbody. (16406728)
2006
29
Correlation between phenotypic characteristics of mononuclear cells isolated from human periapical lesions and their in vitro production of Th1 and Th2 cytokines. (16797478)
2006
30
Fibrinogen and fibrin structure and functions. (16102057)
2005
31
Fluoxetine during pregnancy: impact on fetal development. (16263070)
2005
32
Morphology of the suburethral pubocervical fascia in women with stress urinary incontinence: a comparison of histologic and MRI findings. (16034512)
2005
33
Connexin30 mutations responsible for hidrotic ectodermal dysplasia cause abnormal hemichannel activity. (15213106)
2004
34
Helical CT for nephrolithiasis and ureterolithiasis: comparison of conventional and reduced radiation-dose techniques. (14526095)
2003
35
Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia: a potential role in the pathogenesis of the disease. (12915401)
2003
36
Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. (15618753)
2003
37
Effective diminution of amniotic prostaglandin production by selective inhibitors of cyclooxygenase type 2. (10694339)
2000
38
Nckbeta adapter regulates actin polymerization in NIH 3T3 fibroblasts in response to platelet-derived growth factor bb. (11027258)
2000
39
Ubiquitin and its role in neurodegeneration. (9932397)
1998
40
Otitis externa. (8893215)
1996
41
Ethanol treatment up-regulates the expression of mitochondrial manganese superoxide dismutase in rat liver. (8024580)
1994
42
Suppression of plasma intact parathyroid hormone levels during insulin-induced hypoglycemia in humans. (1592870)
1992
43
Induction of ornithine decarboxylase in normal and protein kinase C--depleted human colon carcinoma cells. (1294268)
1992
44
Cystic mucinous adenocarcinoma of the lung. Two cases of cystic variant of mucus-producing lung adenocarcinoma. (1311665)
1992
45
Imipramine as a discriminative stimulus. (1762063)
1991
46
Demonstration of osteochondritis dissecans of the talus by coronal computed tomographic arthrography. (2605451)
1989
47
Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. (2614466)
1989
48
Sweat gland carcinoma ex eccrine spiradenoma. (2847574)
1987
49
A study of familial combined hyperlipidemia in 11 families. (6671713)
1983
50
Autoradiographic studies of hair growth and rhythm in monilethrix. (5783770)
1969

Variations for Narcolepsy

About this section

Expression for genes affiliated with Narcolepsy

About this section
Search GEO for disease gene expression data for Narcolepsy.

Pathways for genes affiliated with Narcolepsy

About this section

GO Terms for genes affiliated with Narcolepsy

About this section

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:004261310.8HLA-DQA1, HLA-DQB1
2integral component of lumenal side of endoplasmic reticulum membraneGO:007155610.6HLA-DQA1, HLA-DQB1
3trans-Golgi network membraneGO:003258810.3HLA-DQA1, HLA-DQB1, HLA-DRB1
4ER to Golgi transport vesicle membraneGO:001250710.0HLA-DQA1, HLA-DQB1, HLA-DRB1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1immunoglobulin production involved in immunoglobulin mediated immune responseGO:000238110.8HLA-DQB1, HLA-DRB1
2antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIGO:000250410.8HLA-DQA1, HLA-DRB1
3regulation of circadian sleep/wake cycle, sleepGO:004518710.8HCRTR1, HCRTR2
4antigen processing and presentationGO:001988210.6HLA-DQA1, HLA-DQB1, HLA-DRB1
5synaptic transmissionGO:000726810.2ATXN3, HCRT, HTR2A

Sources for Narcolepsy

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet